SUTOL Bio · Drug Delivery Platform

The first gram-scale monthly
oral capsule.

One dose a month. No daily pills, no painful injections. Just continuous therapy from a single capsule you swallow.

Scroll
The Problem

Poor adherence is the #1 avoidable challenge in chronic disease.

It’s most visible in five major conditions where strict, long-term therapy is required, yet where adherence consistently fails.

Opioid Use DisorderSchizophreniaHIVAlcohol Use DisorderBipolar Disorder
Today’s Options Fall Short

Between the two standards of care lies a clear white space.

01Adherence fails

Daily oral pills

Simple and familiar, but effective adherence is unrealistic without caregivers, and missed doses undermine therapy.

02Painful · irreversible

Long-acting injectables

Effective for adherence, but painful, prone to injection complications, and irreversible once administered.

A safe, patient-friendly, cost-effective, reversible, pharmacy-based oral solution that ensures adherence, all without the burdens of injections.

The Solution

One monthly dose.
30+ days of release.

The first gram-scale monthly oral capsule platform. It resides safely in the stomach and releases therapy continuously for over a month. It is reversible, pharmacy-based, and reimbursement-ready.

30+
Days of continuous release
1
Monthly oral dose
Gram
Scale drug payload
5
Target indications
Our Foundation

Built in the Langer & Traverso labs at MIT.

SUTOL Bio was born from six years of translational research at MIT, combining decades of pioneering work in drug delivery with cutting-edge biomedical engineering to create transformative therapies for patients worldwide.

MIT
Origin
6 yrs
Translational research
Cambridge
Massachusetts HQ
Partner With SUTOL

Let’s advance the future of drug delivery.

We’re building the first gram-scale monthly oral capsule. Reach out about partnerships, research collaboration, or investment.

contact@sutolbio.com →